Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810219 · ClinicalTrials.gov registry record · NA
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
A NA study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Cognixion.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06810219: Recruiting NA study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Cognixion.
NCT06810219 is a NA study of ALS (Amyotrophic Lateral Sclerosis) that is actively recruiting participants, run by Cognixion. The registered enrollment target is 10 participants, below the 366-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810219, a NA study of ALS (Amyotrophic Lateral Sclerosis), is actively recruiting participants, sponsored by Cognixion.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and associated communication software. The study duration is 3 months for each participant. The key questions that will be addressed in this study are: 1. How quickly can participants learn and gain confidence with a pure BCI interface. 2. How effective are alternate input modalities including eye tracking for this use case. 3. Identify the extent to which generative AI based personalization impacts the communication quality. Key measures include: ITR - information transfer rate SUS - system usability scale
Conditions Studied
Interventions
- DEVICE Cognixion ONE
Study Locations (1)
California
- Cognixion - Santa Barbara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2025-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06810219
The ClinicalTrials.gov registry entry for NCT06810219 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (97% lower). The listed sponsor is Cognixion, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ALS (Amyotrophic Lateral Sclerosis) appearing as the primary indexed condition, and to 1 intervention - of which Cognixion ONE is the first listed.
NCT06810219 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06810219 about?
NCT06810219 is a clinical study titled "Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS". The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and asso...
What is the current status of trial NCT06810219?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-01-20. Estimated completion is 2025-10-31.
What conditions does trial NCT06810219 study?
This clinical trial studies the following conditions: ALS (Amyotrophic Lateral Sclerosis).
What interventions are being tested in trial NCT06810219?
The interventions under investigation include: Cognixion ONE (DEVICE).
Who is sponsoring clinical trial NCT06810219?
This trial is sponsored by Cognixion, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810219 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ALS (Amyotrophic Lateral Sclerosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Outcome Assessment for AT & BCI
RECRUITING · NA
-
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
RECRUITING · NA
-
Tofersen in Non-SOD1 ALS
RECRUITING · Phase 2
-
ALS Research Collaborative
RECRUITING
-
Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Obi Medical Robot: Evaluating Effectiveness Related to Usability
ACTIVE NOT RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.